Latest News on ARCT

Financial News Based On Company


Advertisement
Advertisement

Under a Nov. 16 deal, 2,466,395 Arcturus Therapeutics (ARCT) shares are issuable to Meiji Seika Pharma.

https://www.stocktitan.net/sec-filings/ARCT/schedule-13g-arcturus-therapeutics-holdings-inc-passive-investment-di-66e4b9677fd2.html
Meiji Seika Pharma Co., Ltd. has reported a 7.88% passive stake in Arcturus Therapeutics Holdings Inc. (ARCT), comprising 2,466,395 shares. This ownership percentage is based on 28,822,514 shares outstanding as of November 3, 2026, plus the shares issuable under a Securities Purchase Agreement dated November 16, 2026. Meiji Seika Pharma holds sole voting and dispositive power over these shares.

Meiji Seika Pharma invests $50M in Arcturus at 80% premium

https://www.streetinsider.com/Corporate+News/Meiji+Seika+Pharma+invests+%2450M+in+Arcturus+at+80%25+premium/27349219.html
Meiji Seika Pharma has invested $50 million in Arcturus Therapeutics Holdings Inc. through an equity purchase, acquiring a 7.9% stake at an 80% premium. The funds will be used by Arcturus to accelerate the development of ARCT-2601 for OTC deficiency, support its cystic fibrosis program, and clinically validate its LUNAR 2.0 mRNA delivery platform. This investment is part of an expanded collaboration that also includes an exclusive license agreement for ARCT-154 technology and a potential pandemic preparedness program in Japan.

Arcturus Therapeutics Holdings Inc. (ARCT) options chain

https://uk.finance.yahoo.com/quote/ARCT/options/?date=1805414400&straddle=false&type=all
This article provides detailed options chain data for Arcturus Therapeutics Holdings Inc. (ARCT) as of November 19, 2026, including both call and put options. It lists various strike prices, last trade dates, prices, bids, asks, changes, volumes, open interest, and implied volatility. The company's stock price was 7.60 USD at market close, down 5.47%.

An investor reports 1.69M Arcturus Therapeutics (ARCT) shares, with voting power over fewer shares.

https://www.stocktitan.net/sec-filings/ARCT/schedule-13g-a-arcturus-therapeutics-holdings-inc-amended-passive-inv-596931ba42d4.html
Amova Asset Management Americas, Inc. has filed an amended ownership report (SCHEDULE 13G/A) for Arcturus Therapeutics Holdings Inc. (ARCT), disclosing beneficial ownership of 1,689,107 shares, representing 5.9% of the class, as of September 30, 2026. The report indicates shared voting power over 1,459,991 shares and shared dispositive power over all 1,689,107 shares, with no sole voting or dispositive power.

Arcturus Therapeutics Holdings Inc. (ARCT) stock price, news, quote and history

https://au.finance.yahoo.com/quote/ARCT/
This article provides a detailed overview of Arcturus Therapeutics Holdings Inc. (ARCT), including its current stock price, historical performance, and key financial metrics. It highlights the company's focus on mRNA medicines for liver and respiratory rare diseases, listing its major technology platforms and therapeutic candidates in various clinical development phases. The report also includes analyst insights, earnings trends, and valuation measures.
Advertisement

Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress

https://www.biospace.com/press-releases/arcturus-therapeutics-announces-third-quarter-2026-financial-results-and-pipeline-progress
Arcturus Therapeutics reported its third-quarter 2026 financial results, highlighting progress in its mRNA therapeutics pipeline. Key updates include accelerated enrollment for the ARCT-032 (CF) Phase 2 study, promising interim data for ARCT-810 (OTC deficiency), and the introduction of LUNAR 2.0™ technology with a new candidate, ARCT-2601. The company also announced pipeline expansion into PKU and gout, successful acquisition of myNEO, and ongoing commercialization of KOSTAIVE® in Japan, while maintaining a strong financial position with a cash runway through 2028.

Arcturus Therapeutics Q3 Results: Net loss narrows to $7.4 million

https://scanx.trade/stock-market-news/companies/arcturus-therapeutics-q3-results-net-loss-narrows-7-4-million/55464165
Arcturus Therapeutics reported a Q3 net loss of $7.4 million, a significant narrowing from $13.4 million in the prior year, with revenue rising to $18.3 million, largely due to a $12 million termination payment from CSL Seqirus. The company maintains a strong cash position of $184.8 million, extending its runway through 2028, and is advancing its LUNAR 2.0 technology and clinical pipeline, including ARCT2601 and ARCT032.

What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:ade387b9f094b:0-what-arcturus-therapeutics-arct-said-on-its-q3-earnings-call/
Arcturus Therapeutics discussed its Q3 earnings, reporting a narrower net loss and sufficient cash to fund operations through 2028. The company provided updates on its cystic fibrosis study, expecting enrollment completion by year-end 2026 and a Phase III decision in 2027, and outlined plans for a next-generation liver disorder treatment to begin dosing in Q1 2027. Additionally, Arcturus detailed its vaccine business strategy post-CSL Seqirus collaboration and its recent acquisition of myNEO for AI capabilities.

Arcturus Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62958900/arcturus-therapeutics-q3-2026-earnings-call-transcript
Arcturus Therapeutics discussed its Q3 2026 financial results, highlighting a decrease in cash to $184.8 million but maintaining a cash runway through 2028. Key developments include promising Phase 2 data for ARCT810 in OTC deficiency, the advancement of ARCT2601 using the more potent LUNAR 2.0 technology, and progress in its cystic fibrosis program ARCT032 with full cohort data expected by Q2 2027. The company also acquired MyNeo to enhance AI-driven mRNA optimization and is commercializing its COVID vaccine, Kostaive, while preparing for EU and UK markets.

A medicine-delivery system was 38 times more potent than a key fat in monkeys

https://www.stocktitan.net/news/ARCT/arcturus-therapeutics-announces-third-quarter-2026-financial-results-7kme7b93khsi.html
Arcturus Therapeutics reported its third-quarter 2026 financial results, highlighting significant progress in its liver therapeutics franchise. The company announced encouraging Phase 2 results for ARCT-810 and introduced LUNAR 2.0™, a next-generation mRNA delivery platform that demonstrated 38-fold greater potency than its predecessor in non-human primates. Arcturus plans to advance several therapeutic candidates, including ARCT-032 for cystic fibrosis and ARCT-2601 for OTC deficiency, with key data presentations and dosing initiations expected in 2027.
Advertisement

Weekly Recap: Q3 results set for Nov. 5 and purchase of 64,483 shares

https://www.tradingview.com/news/tradingview:329c9dd1c0cef:0-weekly-recap-q3-results-set-for-nov-5-and-purchase-of-64-483-shares/
ARK Genomic Revolution ETF (ARKG) purchased 64,483 shares of Arcturus Therapeutics Holdings, Inc. (ARCT) on Friday. Arcturus Therapeutics is scheduled to report its third-quarter 2026 results after market close on November 5, followed by a conference call and webcast.

Arcturus Therapeutics Holdings (ARCT) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/ARCT.US
This article provides a detailed analysis of Arcturus Therapeutics Holdings (ARCT) stock, including its current price, market capitalization, and key financial figures. It evaluates the company's quality, valuation, and growth prospects using various yardsticks and offers hypothetical scenarios for future price performance. The analysis also highlights that ARCT does not pay a dividend and has negative revenue growth in the last quarter.

Arcturus Therapeutics Holdings Inc. (ARCT) Seasonal returns chart

https://uk.finance.yahoo.com/quote/ARCT/seasonality/
The article provides a seasonal returns chart for Arcturus Therapeutics Holdings Inc. (ARCT), showing the average monthly price return from 2016 to 2026. It includes current stock performance data, highlighting a -4.67% change after hours on October 30. The information is presented within the Yahoo Finance platform, focusing on investment analysis.

Two firms report the same Arcturus Therapeutics (ARCT) stake in an amended disclosure.

https://www.stocktitan.net/sec-filings/ARCT/schedule-13g-a-arcturus-therapeutics-holdings-inc-amended-passive-inv-44bb4d4c4351.html
Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have filed an amended ownership report (SCHEDULE 13G/A) for Arcturus Therapeutics Holdings Inc. (ARCT). Both entities report beneficial ownership of 1,689,107 shares, representing 5.9% of the class, with shared voting and dispositive power. The securities are ultimately owned or deemed beneficially owned by their subsidiary, Amova Asset Management Americas, Inc.

(ARCT) and the Role of Price-Sensitive Allocations

https://news.stocktradersdaily.com/news_release/8/ARCT_and_the_Role_of_Price-Sensitive_Allocations_102726093202_1793107922.html
This article provides an AI-generated analysis of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), indicating weak near and mid-term sentiment despite a positive long-term outlook. It details specific institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.
Advertisement

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

https://finance.yahoo.com/healthcare/articles/arcturus-therapeutics-report-third-quarter-200100252.html
Arcturus Therapeutics Holdings Inc. announced it will release its third-quarter financial results for the period ending September 30, 2026, after market close on Thursday, November 5, 2026. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a corporate update. Arcturus is a messenger RNA medicines company developing liver and respiratory therapeutics with various enabling technologies.

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

https://www.biospace.com/press-releases/arcturus-therapeutics-to-report-third-quarter-financial-results-and-provide-corporate-update-on-november-5-2026
Arcturus Therapeutics Holdings Inc. announced it will release its financial results for the quarter ended September 30, 2026, after the market close on Thursday, November 5, 2026. The company will also host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the results and provide a corporate update. Arcturus is a messenger RNA medicines company focused on developing liver and respiratory therapeutics, with strategic collaborations and a pipeline including programs in cystic fibrosis, OTC deficiency, phenylketonuria, and Gout.

Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/ARCT/
Arcturus Therapeutics Holdings Inc. (ARCT) is a messenger RNA medicines company developing treatments for liver and respiratory rare diseases, with key platforms including STARR and LUNAR. The article provides a detailed financial overview, including its stock performance, key financial metrics, earnings trends, and analyst ratings. As of October 26, 2026, its stock price was $9.91, showing a 61.66% YTD return, and analysts have an average target estimate of $23.80.

Arcturus Therapeutics Holdings Inc. Estimates – NASDAQ:ARCT

https://www.tradingview.com/symbols/NASDAQ-ARCT/financials-estimates/
This article from TradingView provides an overview of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) financial actuals and analyst estimates. It allows users to explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various estimates and visualizing trends over time. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.

Arcturus Therapeutics Holdings Inc. (ARCT) options chain – Yahoo Finance

https://sg.finance.yahoo.com/quote/ARCT/options/?date=1805414400&straddle=false&type=all
This Yahoo Finance page displays the options chain for Arcturus Therapeutics Holdings Inc. (ARCT) with data delayed by 15 minutes. It lists both call and put options with an expiration date of March 19, 2027, including strike prices, last trade dates, last prices, bid/ask, change, volume, open interest, and implied volatility. The stock closed at $10.34 on October 16 at 4:00:01 pm GMT-4.
Advertisement

Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call

https://www.benzinga.com/news/26/10/62347254/transcript-arcturus-therapeutics-q2-2026-earnings-conference-call
Arcturus Therapeutics reported its Q2 2026 earnings, highlighting continued progress in its rare disease pipeline, including ARCT032 for cystic fibrosis and ARCT810 for OTC deficiency, with key milestones like Phase 2 study advancements and enrollment completion. The company also announced the regaining of global rights to its self-amplifying mRNA platform and COVID vaccine, Kostaive, after concluding its collaboration with CSL Seqirus, which strengthens its strategic control over its vaccine portfolio. Despite a decrease in revenue due to the CSL collaboration termination, Arcturus maintains a strong cash position and expects a decision on advancing ARCT032 to Phase 3 in Q4 2026, alongside further data and regulatory discussions for the OTC program and exploring commercial and partnership opportunities for its vaccine assets.

FEDERATED HERMES, INC. Trims Arcturus Therapeutics Holdings Inc (ARCT) Stake -- Shares Look 467% Overvalued on GF Value

https://www.gurufocus.com/news/9122116/federated-hermes-inc-trims-arcturus-therapeutics-holdings-inc-arct-stake-shares-look-467-overvalued-on-gf-value
FEDERATED HERMES, INC. has significantly reduced its stake in Arcturus Therapeutics Holdings Inc (ARCT) by 49.21%, selling 1,625,571 shares at $13.69 each. This move leaves the investment firm with 1,678,069 shares, representing a small portion of its portfolio and 5.90% of Arcturus's outstanding shares. The decision reflects concerns over Arcturus's valuation, as GuruFocus estimates the stock to be 467% overvalued, coupled with weak financial health and profitability metrics despite its mRNA technology and commercial milestone in Japan.

A trust joins the reporting parties for 1.68M Arcturus Therapeutics (ARCT) shares.

https://www.stocktitan.net/sec-filings/ARCT/schedule-13g-a-arcturus-therapeutics-holdings-inc-amended-passive-inv-06cd3ccd981f.html
Federated Hermes, Inc. and Voting Shares Irrevocable Trust have filed an amended ownership report for Arcturus Therapeutics Holdings Inc. (ARCT), disclosing beneficial ownership of 1,678,069 shares, representing 5.90% of the common stock. The filing details both sole and shared voting and dispositive powers among Federated Hermes, the Trust, and individual trustees Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue. The reporting parties disclaim beneficial ownership of securities held by Managed Funds.

Discipline and Rules-Based Execution in ARCT Response

https://news.stocktradersdaily.com/news_release/89/Discipline_and_Rules-Based_Execution_in_ARCT_Response_100626080601_1791331561.html
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is exhibiting neutral near-term sentiment that could lead to mid-term weakness, marked by a mid-channel oscillation pattern. AI models have generated three trading strategies: a long position trading strategy, a breakout strategy, and a short risk hedging strategy, each with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 121.0:1 risk-reward short setup targeting a 32.2% downside with only 0.3% risk.

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform

https://finance.yahoo.com/healthcare/articles/arcturus-highlights-arct-810-phase-030209888.html
Arcturus Therapeutics announced encouraging preliminary Phase II data for its ARCT-810 program for OTC deficiency, showing normal ammonia levels and reduced glutamine in participants with mild to moderate adverse events. The company also introduced LUNAR 2.0, a new delivery platform offering significantly higher protein expression, which will be incorporated into ARCT-2601 for potential lower doses and shorter infusions. Arcturus plans a Phase II/III pediatric trial in late 2027 and is expanding its preclinical mRNA programs for PKU and gout, alongside acquiring computational immunology company myNEO.
Advertisement

Arcturus stock upgraded to Buy at Citi (ARCT:NASDAQ)

https://seekingalpha.com/news/4646709-arcturus-stock-upgraded-buy-at-citi
Citi has upgraded Arcturus Therapeutics (ARCT) stock to Buy from Neutral following positive mid-stage trial data for its experimental liver disease drug, ARCT-810. Analyst Yigal Nochomovitz cited the promising results for the messenger RNA therapy designed to treat ornithine transcarbamylase deficiency.

Arcturus Therapeutics Releases ARCT-810 Phase 2 Clinical Results and mRNA Platform Update

https://kalkinemedia.com/us/news/announcements/arcturus-therapeutics-releases-arct-810-phase-2-clinical-results-and-mrna-platform-update
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has announced the presentation of Phase 2 clinical trial data for its ARCT-810 candidate and provided an update on its mRNA delivery platform. This information was disclosed via a Form 8-K filing on September 23, 2026, which included a presentation and a press release summarizing the data. The filing ensures compliance with Regulation FD, mandating broad disclosure of material nonpublic information.

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

https://www.biospace.com/press-releases/arcturus-therapeutics-announces-interim-otc-deficiency-phase-2-results-and-introduces-lunar-2-0-next-generation-mrna-delivery-platform
Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810 in ornithine transcarbamylase (OTC) deficiency, demonstrating safety and efficacy in managing key biomarkers. The company also introduced LUNAR 2.0™, a next-generation mRNA delivery platform showing significantly higher protein expression, which will be used for ARCT-2601, a new therapeutic candidate for OTC deficiency. Additionally, Arcturus plans to acquire myNEO, an AI discovery company, to enhance mRNA design and target identification capabilities.

Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8

https://finance.yahoo.com/markets/stocks/articles/citigroup-upgrades-arcturus-therapeutics-buy-103506942.html
Citigroup has upgraded Arcturus Therapeutics (ARCT) to a "Buy" rating from "Neutral," also increasing its price target to $20 from $8. The article notes that Arcturus Therapeutics has an average rating of "buy" and a mean price target of $23.20. The full details of this analysis are available to premium subscribers.

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

https://www.businesswire.com/news/home/20260923761420/en/Arcturus-Therapeutics-Announces-Interim-OTC-Deficiency-Phase-2-Results-and-Introduces-LUNAR-2.0-Next-Generation-mRNA-Delivery-Platform
Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810 in ornithine transcarbamylase (OTC) deficiency, showing it was generally safe and well-tolerated while improving key biomarkers. The company also introduced LUNAR 2.0™, a next-generation mRNA delivery platform demonstrating significantly higher protein expression, and plans to integrate ARCT-2601, utilizing LUNAR 2.0™, into the ongoing Phase 2 study. Additionally, Arcturus will acquire myNEO, an AI discovery company, to enhance mRNA design and target identification capabilities.
Advertisement

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

https://finance.yahoo.com/healthcare/articles/arcturus-therapeutics-present-ornithine-transcarbamylase-130000125.html
Arcturus Therapeutics will host a virtual presentation on September 23, 2026, to discuss Phase 2 clinical data for ARCT-810, their mRNA therapeutic for Ornithine transcarbamylase (OTC) deficiency, and provide an update on their mRNA liver therapeutics platform. Dr. Marshall Summar, an expert in rare diseases and OTC deficiency, will participate. ARCT-810 aims to restore functional OTC enzyme in the liver to address this life-threatening metabolic disorder.

ARCT Stock Price and Chart — NASDAQ:ARCT

https://www.tradingview.com/symbols/NASDAQ-ARCT/
Arcturus Therapeutics Holdings Inc. (ARCT) is a late-stage clinical mRNA medicines and vaccine company focusing on infectious diseases and rare conditions. Recent updates include dosing for ARCT-2601 in OTC deficiency patients and an upgrade to "Buy" by Citi after positive Phase 2 data for ARCT-810. The stock has shown significant volatility, with recent price decreases, but analysts have a wide forecast range.

Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead

https://www.investing.com/news/transcripts/arcturus-therapeutics-at-cantoral-global-healthcare-conference-data-catalysts-ahead-93CH-4896485
Arcturus Therapeutics presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, highlighting its pipeline with three key programs: an OTC deficiency therapy, an inhaled cystic fibrosis treatment, and a self-amplifying mRNA platform. The company anticipates several critical data readouts and decisions, including Phase II data for its OTC deficiency program and a Q4 decision on its cystic fibrosis treatment, which could unlock significant funding. Arcturus emphasized its differentiated technology, strong safety profiles, and strategic partnerships as it aims to address unmet medical needs and generate non-dilutive funding.

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

https://www.businesswire.com/news/home/20260831173128/en/Arcturus-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences
Arcturus Therapeutics announced its participation in several investor conferences in September 2026, including the Wells Fargo, Citi's, Cantor Fitzgerald, H.C. Wainwright, and ROTH conferences. The company, a messenger RNA medicines company, will present on its pipeline and technologies, including its LUNAR® and STARR® platforms. Interested parties can find webcast links for these events on the Investor Relations/Events section of Arcturus’ website.

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

https://finance.yahoo.com/healthcare/articles/arcturus-therapeutics-participate-upcoming-investor-200100593.html
Arcturus Therapeutics Holdings Inc. announced its participation in several upcoming investor conferences in September 2026, including events hosted by Wells Fargo, Citi, Cantor Fitzgerald, H.C. Wainwright, and ROTH. The company, a messenger RNA medicines developer, will engage in fireside chats, presentations, and investor meetings to discuss its focus on liver and respiratory rare disease therapeutics.
Advertisement

Arcturus Therapeutics (ARCT) Short Interest & Short Float | Updated Sep 2026

https://www.marketbeat.com/stocks/NASDAQ/ARCT/short-interest/
Arcturus Therapeutics (ARCT) reported a short interest of 6.53 million shares as of August 14, 2026, representing 27.93% of its public float, a decrease of 9.45% from the prior report. The short interest ratio is 9.9 days to cover, indicating a high level of pessimism among investors. Short interest has fluctuated significantly over the past year, with the highest percentage of float shorted reaching 38.3% in November 2025.

Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ

https://stockstotrade.com/quote/ARCT
Arcturus Therapeutics Holdings Inc. (ARCT) saw a significant price increase of 23.12%, adding $2.54 to its stock value. The article provides live quotes and charts for ARCT but notes that there is no current analyst rating data or earnings information available for the company. It also includes disclaimers about investment risks and the informational nature of the content.

ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’

https://stocktwits.com/news-articles/markets/equity/arct-surges-over-60-toward-best-week-in-year-as-moderna-cancer-win-lifts-sector-retail-says-arcturus-getting-harder-to-dismiss/cZYfk0XRJVh
Arcturus Therapeutics (ARCT) shares surged over 60% in a week, driven by positive late-stage results from Merck and Moderna's mRNA cancer vaccine trial, which boosted the broader mRNA sector. Despite being a smaller player, Arcturus benefited from the enthusiasm and its own pipeline progress in rare diseases, leading to "extremely bullish" retail sentiment. The company is advancing treatments for cystic fibrosis and OTC deficiency, with key data readouts expected in Q3 and Q4 2026.

ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows

https://stockstotrade.com/news/arcturus-therapeutics-holdings-inc-arct-news-2026_08_19/
Arcturus Therapeutics stock (ARCT) surged nearly 20% due to positive sentiment surrounding its mRNA pipeline, including the regaining of global rights to its KOSTAIVE vaccine and a growing cash reserve of $191.5 million. Despite a slight revenue miss and continued losses in Q2, the company's strong balance sheet and advancing Phase 2 trials for ARCT-032 and ARCT-810 are providing catalysts for traders. Analysts maintain a "Buy" rating, seeing the recent collaboration changes and cash injection as beneficial for the company's future.

Liquidity Mapping Around (ARCT) Price Events

https://news.stocktradersdaily.com/news_release/8/Liquidity_Mapping_Around_ARCT_Price_Events_081626083801_1786883881.html
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It highlights a significant risk-reward short setup and provides specific trading strategies (Long, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strength, support, and resistance levels for ARCT.
Advertisement

We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate

https://www.moomoo.com/news/post/74722417/we-re-keeping-an-eye-on-arcturus-therapeutics-holdings-nasdaq
This article examines Arcturus Therapeutics Holdings' cash burn rate and its implications for the company's future. It highlights the company's current cash reserves and how long they might last given its operating expenses. The analysis is crucial for investors to understand the company's financial health and potential need for future funding.

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

https://es.tradingview.com/news/marketbeat:99f7144b7094b:0-arcturus-therapeutics-eyes-phase-iii-cf-call-otc-data-as-vaccine-funds-pipeline/
Arcturus Therapeutics is focusing its mRNA platform on rare diseases like cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency, utilizing its vaccine business to fund these therapeutic developments. The company expects to decide on advancing its inhaled mRNA treatment for CF (ARCT-032) into Phase III in the fourth quarter, based on ongoing Phase II data. Additionally, Arcturus anticipates reporting data and regulatory updates for its injectable mRNA therapy for OTC deficiency (ARCT-810) before September 30, while maintaining a cash runway through 2028.

H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9

https://www.moomoo.com/news/post/74505457/hc-wainwright-maintains-arcturus-therapeutics-arctus-with-hold-rating-maintains
H.C. Wainwright has reiterated its Hold rating on Arcturus Therapeutics (ARCT.US) and maintained its target price at $9. This indicates that the firm sees the stock as likely to perform in line with the broader market and does not anticipate significant price movement from current levels.

BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23

https://www.moomoo.com/news/post/74413017/btig-maintains-arcturus-therapeutics-arctus-with-buy-rating-maintains-target
BTIG has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) and maintained its price target at $23. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen

https://www.marketbeat.com/instant-alerts/arcturus-therapeutics-nasdaqarct-rating-increased-to-sell-at-wall-street-zen-2026-08-09/
Wall Street Zen upgraded Arcturus Therapeutics (ARCT) from "strong sell" to "sell," while Weiss Ratings maintained its "sell (D-)" rating. Despite these downgrades, MarketBeat's analyst consensus remains a "Moderate Buy" with an average price target of $24.25. The clinical-stage biotech company, which develops mRNA medicines and vaccines, reported a quarterly loss of $0.84 per share, beating expectations, but revenue of $2.96 million missed estimates.
Advertisement

Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS

https://www.marketbeat.com/instant-alerts/arcturus-therapeutics-nasdaqarct-announces-earnings-results-beats-estimates-by-016-eps-2026-08-07/
Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings, reporting an EPS of ($0.84), beating analyst estimates by $0.16, despite revenue of $2.96 million falling short of expectations. The company provided updates on clinical trials for ARCT-810 and ARCT-032, and regained global rights to its KOSTAIVE vaccine portfolio after ending a collaboration with CSL. Despite a sharp decline in revenue and cash, the company states it has sufficient cash runway through 2028.

Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside

https://www.tradingview.com/news/tradingview:8aa08fd27f51d:0-arcturus-therapeutics-holdings-inc-stock-12-month-price-target-cut-to-20-2-implies-232-upside/
Arcturus Therapeutics Holdings Inc.'s average stock price target has been reduced from $20.6 to $20.2 by 10 analysts, still suggesting a significant 232% potential upside based on its closing price on August 6. Despite the target cut, the consensus rating from 13 analysts remains a "Buy," with 10 recommending Buy, 3 Hold, and 0 Sell. Investors can find more detailed price target data and analyst recommendations on TradingView's platform.

CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20

https://www.moomoo.com/news/post/74333388/ccorf-maintains-arcturus-therapeutics-arctus-with-buy-rating-cuts-target
CCORF has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) but has adjusted its target price downwards to $20. This indicates a continued positive outlook on the stock, albeit with a revised valuation.

Arcturus Therapeutics Q2 Earnings Call Highlights

https://es.tradingview.com/news/marketbeat:2a9ab026e094b:0-arcturus-therapeutics-q2-earnings-call-highlights/
Arcturus Therapeutics announced progress in its Q2 earnings call for 2026, advancing its rare-disease pipeline, completing enrollment for its Phase II OTC deficiency study, and regaining global rights to its KOSTAIVE COVID-19 vaccine and mRNA platform. The company also reported on its cystic fibrosis treatment candidate, ARCT-032, and its financial position, including cash and cash equivalents of $191.5 million as of June 30. Revenue decreased due to the end of the CSL collaboration, but the company's cash runway extends through the end of 2028.

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

https://www.biospace.com/press-releases/arcturus-therapeutics-announces-second-quarter-2026-financial-results-and-pipeline-progress
Arcturus Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including continued progress in the ARCT-032 Phase 2 cystic fibrosis study and completed enrollment for the ARCT-810 Phase 2 OTC deficiency study. The company regained global rights to KOSTAIVE® and its infectious disease vaccine portfolio, receiving $12 million in cash and $16 million in released liabilities. Despite a decrease in revenue compared to the previous year, Arcturus maintains a strong cash position with a runway through 2028, supported by strategic collaborations and a focus on rare disease programs.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement